KRAS and neoplasm: First, genetic heterozygosity within the tumor might result in mutation levels below the analytical sensitivity of dideoxy sequencing (10 - 30%)[17,29], whereas the detection limit of HRMA was previously reported at 3%[17] and the KRAS StripAssay® detect at least 1% mutated alleles.